The new migraine treatment ‘Emgality’ is seeking reimbursement benefits in Korea.

According to industry officials, Eli Lilly Korea has recently submitted a reimbursement application for its calcitonin gene-related peptide (CGRP)-targeted migraine prevention therapy ‘Emgality (galcanezumab).’

Emgality, the first CGRP-targeted migraine prevention treatment to be introduced in Korea, selectively binds to CGRP, a substance known to be a key cause of migraine, and blocks its binding to the receptor. The drug was designated as an orphan drug in April of last year and approved in September of the same year. Recently, Emgality was additionally approved by the FDA as a treatment for e